Introduction

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It primarily infects the lungs, but it can also infect the digestive organs, lymph, and bones. Approximately 10% of the M. tuberculosis-infected people develop tuberculosis. The onset of tuberculosis is more frequent in men and tends to increase with aging. People with lower immunity, old age, diabetes; who use immunosuppressive drugs; and people with HIV/AIDS infection are more likely to develop tuberculosis [1].

Tuberculosis remains an important problem that threatens public health throughout the world, including Korea. Tuberculosis-infected people in Korea number an estimated 15 million, which is one-third of the total population [2]. Each year Korea witnesses 30,000–35,000 newly diagnosed cases of TB, which is the highest incidence among infectious diseases in Korea, and approximately 75,000 people are treated [3,4]. The World Health Organization (WHO) reports a TB incidence rate of 97 per 100,000 people in Korea, and Korea is among the intermediate burden countries [1].

Since 1962, Korea has begun to control TB on a national basis with its National Tuberculosis Control Plan. The national tuberculosis status survey has been conducted every 5 years since 1965 until 1995. During this period, the incidence rate has sharply decreased and the prevalence rate has also decreased from 5% to 1% [2]. With a decrease of TB patients and low responding rate of the national survey, the national TB status has been identified on a report basis since 2000 [5]. The scale of TB patients has not been decreased, but remains steady [3,4] (Figure 1).

Deaths and the incidence rate caused by TB are also the highest among all infectious diseases. In fact, because of TB infection, Korea has the highest incidence and deaths among the 36 Organisation for Economic Co-operation and Development (OECD) countries and is 70^th–90^th among WHO member states [1]. The patients are mostly distributed in their 20–40s (40%), which is a typical aspect of developing countries. Tuberculosis in Korea was mostly controlled by public health centers, but private hospitals have gradually taken over this role since the mid-1990s, and above 85% of TB patients are treated and controlled in private hospitals since 2010 [3,4,6].

Tuberculosis relapse is divided into two classes: (1) a patient in whom the initial onset has been treated, but the existing M. tuberculosis reactivates into a second onset of TB; and (2) a patient with reinfection with new M. tuberculosis [7,8]. To distinguish between these two classes, genotyping is necessary but unfeasible for every patient. Korea does not identify these two classes [i.e., relapse (reactivated onset) and reinfection] [9]. The relapse rate differs by a country's incidence and control: 0–27% of TB relapses occur within 2 years after treatment completion and most relapses occur within 5 years; however, some relapses occur 15 years after treatment. In low incidence countries, most relapses occur within 2 years of treatment completion; however, in high incidence countries, relatively high relapse 2 years after treatment completion can be attributed to the relatively high chance of reinfection [10–12].

Among many indicators to control TB, the relapse rate is an indicator that can be used to evaluate a community's level of tuberculosis control [13]. According to the Korea Tuberculosis Annual Report, approximately 12% of annual reported cases are reported as relapse tuberculosis [3,4]. However, no national level study has been conducted with the exception of studies on specific medical institution or TB patients with antimicrobial resistance. This study aims to estimate the relapse rate of TB in Korea by using national data on reported cases and find factors related to the relapse of TB.

Materials and methods

2.1 Study participants

The data source is the national reported cases of TB patients registered in the TB Integrated Information System (TBnet). The study participants were TB patients registered in TBnet in 2005. The exclusion criteria were patients with duplicate reports, foreigners, chronic TB cases, death after treatment, and changed diagnosis. Among 46,969 patients registered in TBnet in 2005, the following were excluded: 718 duplicate reports, 388 foreigners, 49 changed diagnosis, 262 deaths after treatment, and 118 chronic cases. In this study, 45,434 TB patients were analyzed (Figure 2).

2.2 Methods

We checked whether the patients in the study had been reported again in the TBnet during the following 5 years (i.e., 2006–2010). We selected the following variables as related factors in the reported data: age, sex, region, registration type, disease code (based on the International Classification of Disease-10, available at http://apps.who.int/classifications/icd10/), medicine, and treatment results. The region was classified and coded from 1 to 16 with no specific region name. Registration types were “new case”, “relapse”, “treatment after failure”, “treatment after default”, “transfer in”, or “other”. The disease codes of the ICD-10 were reclassified as follows: “sputum smear-positive pulmonary TB” (A15.0); “sputum smear-negative pulmonary TB” (A15.1, A15.2, A15.3, A16.0, A16.1, A16.2, A19.0-A19.9); and “extrapulmonary TB” (A15.4-A15.9, A16.3-A16.9, A17.x, A18.x). Based on the medication, patients were divided into five groups: Group 1 patients were treated with isoniazid, rifampin, pyrazinamide, and ethambutol. Groups 2–5 patients were classified according to the other medicines. Treatment results were classified as “cure”, “complete”, “failure”, “default”, “transfer out”, and “others”.

The data used in this study did not require the submission of informed consent from the patients because the report is mandatory by the tuberculosis prevention law. The author received the data with no personal information and the computer to access the data was not connected with an outside network. This study was approved by the Institutional Review Board of the Korea Centers for Disease Control and Prevention, Cheongju, Korea (No. 2012-05CON-15-P).

2.3 Data analysis

Descriptive epidemiological analysis was conducted for the general characteristics of study patients. The Chi-square test was performed for major variables and relapse with 0.05 significance level. Multivariate logistic regression analysis was conducted to analyze factors associated with relapse of TB. SAS 9.2 for Windows (SAS Inc., Cary, NC, USA) was used for data analysis.

Results

3.1 General characteristics and variables

The characteristics of TB patients registered in TBnet 2005 were the following. More than one-half (62.1%) of the patients were men. The average age was 47.5 ± 19.8 years. Most patients were above the age of 20 years: 214 patients were aged < 10 years; 2,443 patients were aged 10–19 years; 8134 patients were aged 20–29 years; 7,299 patients were aged 30–39 years; 7338 patients were aged 40–49 years; 5,675 patients were aged 50–59 years; 6,293 patients were aged 60–69 years; and 8,038 patients were aged ≥ 70 years. The registration types were the following: 34,569 new cases; 5611 relapses; 654 re-registration after cease; 1,812 move-in; and 2,505 others. There were 15,745 sputum smear-positive pulmonary TB cases; 23,437 sputum smear-negative pulmonary TB cases; and 6,216 extrapulmonary TB cases. Group 1 medicines alone were used by 43,276 patients, but 2,158 patients used the other medicine groups. Based on age, location of medical institution, registration type, and TB type, the number of male patients was statistically significantly greater than the number of women (Table 1).

3.2 Factors associated with the relapse rate

Among 45,434 patients in 2005, 4,371 persons were re-reported during the following 5-year period (i.e., 2006–2010). The total number of re-reported cases was 5072 reports with the exclusion of 564 duplicate reports. Therefore, the 5-year relapse rate of TB was 9.62, based on the number of patients. The annual relapse rate decreased yearly: 2,189 (4.8%) patients in 2005; 1,082 (2.4%) patients in 2007; 714 (1.6%) patients in 2008; 615 (1.4%) patients in 2009; and 472 (1.0%) patients in 2010. The first 2 years had 65% of relapses in the 5-year period (Figures 3 and 4).

The Chi-square test showed that the relapse rate and study variables were all independently related. Men (10.86%) more frequently relapsed, compared to women (7.59%). The relapse rate was highest among patients in their 40s (11.50%), followed by patients in their 50s (10.27%), 60s (10.03%), 30s (9.81%), 20s (8.81%), 70s (8.53%), 10s (7.65%), and < 10 years (3.27%). Patients (9.87%) in private medical institutions had slightly more relapses than patients (8.97%) in public health centers. Patients with re-registration after cease showed the highest relapse rate (25.08%), followed by failure of the first treatment (21.55%), relapse (14.95%), others (12.14%), move-in (10.49), and new cases (8.14%). The highest relapse rate occurred with sputum smear-positive pulmonary TB (12.37%), followed by sputum smear-negative pulmonary TB (8.72%) and extrapulmonary TB (6.05%). More relapsed patients (15.89%) had used medicines from Group 2 to Group 5, compared to patients using Group 1 medicines (9.31%). The location of the medical institutions also showed a significant difference: the highest rate was 14.01% and the lowest rate was 6.93% (Table 2).

Among TB patient data of public health centers for which treatment results were available, the relapse rate was independently associated with sex, age, registration type, TB type, treatment result and region, based on the Chi-square test. The relapse rate was higher in men (10.0%) than in women (6.8%). The age-related relapse rate showed that the < 10 years age group had the highest rate (20.0%), followed by patients in their 20s (8.4%); 30s (9.3%); 40s (10.2%); 50s (10.3%); 60s (10.0%); and 70s (7.8%). However, the < 10 year age group size was only five patients; therefore, the relapse rate of the group could not be an effective value. Patients with first treatment failure experienced the greatest relapse (40%), followed by re-registration (21.2%), relapse (14.9%), others (10.8%), new cases (7.5%), and move-out (7.4%). However, the size of first treatment failure group was also small and insufficient to justify the results.

Based on the tuberculosis type, the relapse rate of sputum smear-positive pulmonary TB was 11.8%; sputum smear-negative pulmonary TB, 7.0%; and extrapulmonary TB, 5.4%. Treatment results showed that patients with treatment failure had the highest relapse rate (50%), followed by treatment cease (24.0%), others (17.1%), move-out (11.4%), completion (11.1%), and full recovery (7.3%). The regional relapse rate showed a difference: the highest rate was 12.32% and the lowest rate was 5.42%.

The Chi-square test showed that the relapse rate in public health center patients with treatment results were associated with age, sex, registration type, TB type, and medicine. With these variables, multivariate logistic regression was performed to confirm that most related variables in the Chi-square test were also related.

The relapse rate for all study patients was higher in men than in women with an odds ratio of 1.33 [95% confidence interval (95% CI), 1.24–1.43]. Because of the small size of the < 10-year-old group, the reference was patients in the 10s age group and the odds ratio of relapse in the 40s age group was significant at 1.20 (95% CI, 1.01–1.42); however, the other age groups did not show a significant difference. Compared to users of private medical institutions, public health center users were more likely to relapse with an odds ratio of 1.23 (95% CI, 1.14–1.33). Re-registration after first treatment failure had the highest odds ratio of 3.18 (95% CI, 2.64–3.83), followed by first treatment failure [odds ratio of 2.02 (95% CI, 1.50–2.72); and relapse registration [odds ratio of 1.76 (95% CI, 1.61–1.91)]. Move-out and other reasons were associated with an odds ratio of 1.23 (95% CI, 1.05–1.44) and 1.51 (95% CI, 1.33–1.71), respectively. Patients with sputum-positive TB had more relapses, compared to patients with sputum negative TB, with an odds ratio of 1.42 (95% CI, 1.33-1.52). Patients treated by Group 1 medicines had more relapses than patients treated by Groups 2–5 medicines with an odds ratio of 1.32 (95% CI, 1.16–1.50). The region also showed various associations (odds ratio of 0.85–1.85; Table 3).

For patients in public health centers, all dropout records were input and a multivariate logistic regression was performed. Public health centers rarely used Group 2 medicines (< 1%); therefore, they were excluded in the analysis. In the multivariate analysis among the patients in public health centers, the relapse rate was not associated with age. This finding was different from the analysis with total study subjects. The related variables [denoted by (odds ratio, 95% CI)] were men (1.32, 1.14–1.52), relapse (1.87, 1.60–2.18), and re-registration after cease (2.32, 1.64–3.29). However, there was no association with move-out or others. The treatment failure group was too small to confirm significance. Sputum-positive TB (1.66, 1.45–1.88), treatment failure (10.26, 5.95–17.68), treatment cease (3.77, 3.03–4.68), move-out (1.42, 1.17–1.73), and other dropout (2.41, 1.80–3.25) were associated with relapse (Table 4).

Discussion

4.1 Interpretation of the results

This study aimed to identify factors associated with relapse of TB in Korea by using national reported case data. The relapse rate for a 5-year period in this study was 9.6%, which was lower than the rate reported in the Annual Report on the Notified Tuberculosis Patients in Korea [3,4]. The relapse rate did not include relapse after the 5-year period. The reported rate of private medical institutions was estimated below 60%. The TB infection of risk groups such as residents in unauthorized facilities and homeless people was not identified. For various reasons, the relapse rate in this study was underestimated in comparison to the annual reported relapse rate. The relapse of TB can be divided into two categories: (1) recurrence by reactivation of same bacteria in the previous infection and (2) reinfection. These two factors can be confirmed with genotyping, but in this study with national reported cases, the patients' clinical data could not be attained; therefore, recurrence and reinfection could not be identified [7,9]. Korea does not conduct TB DNA finger printing tests on TB patients, and a special methodology is necessary to distinguish between these two aspects. A literature review indicates that within 2 years of treatment more cases of recurrences result from reactivation of existing bacteria and more cases of reinfection occur after 2 years of treatment with another person's TB bacteria. A high TB incidence rate is controversially associated with reinfection [10,14]. In this study, 42% of the relapsed TB patients had relapsed within 1 year and 65% of patients had relapsed within 2 years.

If we were to extend the follow-up period, the relapse rate within 2 years would be lower. This finding contrasted with the results of existing studies. A study conducted in one private hospital revealed that 80% of TB patients with completion of treatment needed additional treatment [8,9,15]. Compared to the existing study in Korea, the relapse rate in 2 years after treatment was lower and closer to the other country's study results [8,9,15].

The relapse of TB was higher in men, which is the case with TB infection. The relapse rate by sex was higher in some studies, but other studies show no relation [16,17]. This study also confirmed that men relapsed more, based on Chi-square and multivariate regression analyses. Relapse occurred more in patients in the 40s, 50s, and 60s age groups. This may be associated with the increase of TB patients and latent tuberculosis infection. However, there was no relation between age and the relapse rate in this study's multivariate logistic regression with patients registered in the public health centers with treatment results available. This suggests that previous treatment results, rather than age effect, affects the relapse of TB.

To confirm the same results in the all TB patients, it is necessary to secure treatment results in patients treated and controlled by private medical institutions. Among patients using private medical institutions, the relapse rate was higher compared to the rate of public health centers. This finding could be explained in that first infected TB patients treated by Group 1 medicines were mostly treated in public health centers, whereas incurable TB patients with relapsed TB or antimicrobial-resistant TB were treated in private medical institutions. Furthermore, treatment dropout is also relatively higher in private medical institutions [6].

Compared with new cases, relapsed patients, treatment failure patients, and re-registered patients after cease of treatment were more highly relapsed. It may be that patients with second treatment are more relapsed, compared to patients with new cases. In particular, patients with treatment failure could be relapsed again, even with full recovery after long-term treatment. These results corresponded with the results of existing studies that factor in relapse is previous TB infection [14].

The relapse of patients with treatment failures were also far higher (Tables 4 and 5). Treatment failure is mostly attributable to antimicrobial-resistant tuberculosis. The relapse could be high, even after full recovery after long-term treatment.

It could be a good method to lower the relapse by managing the first TB-infected patients to take medicine thoroughly and periodically not to fail treatment [15]. For convenience of intake, the everyday intake of medicines is better for lowering TB relapse, compared to taking medicines two or three times weekly. Directly observed therapy (DOT) in general lowers the relapse rate, but some researchers are suspicious of the effectiveness of DOT [8,18]. The relapse rate with short-term chemical therapy (e.g., rifampin) is < 5%; however, this studys relapse rate of patients with full recovery using public health centers with treatment results was 7.3%. This rate was higher than the rate reported in existing studies [19]. Patients with an irregular medicine intake period, a cavity observed on chest X-ray, and sputum-positive results after a 2 month-intake of medicine have a relapse rate >5%; however, in this study, no clinical data were secure and could not be confirmed [18]. The completion patients' relapse rate was 11.7%, which is higher than the relapse rate of patients with full recovery.

Without confirming negative TB, completion patients, who were in reality treatment failures, could be reported as relapse patients [20]. Move-out patients also showed a higher relapse rate. This may be because the patients were no longer treated without move-in to other medical institutions. However, more study on conformity is needed.

4.2 Strength and limitations

Studies outside Korea indicate relapse factors of TB such as irregular intake of medicine, alcoholism, smoking, previous history of TB infection, and diseases accompanied by a decline in immunocompetence [15]. This study could not investigate the associated factors of behavior or clinical situations of patients and did not confirm factors. Furthermore, no questionnaires were conducted to investigate the behaviors and socioeconomic characteristics of patients and this study has limited variables [15]. Private medical institution had limited results after dropout of the registry; therefore, no relapse rate was calculated for the dropout patients.

Medical doctors and medical institution are required to report TB patients, but it is not mandatory to report treatment and control of TB patients. To overcome this limit, the National Health Insurance data should be utilized for the visit period, TB bacteria test date, medicine intake information, insurance type, and insurance premium. This current study's limitation would also be overcome by surveying a sample representative population to cover health behavior and socioeconomic status. In the disease code after 2008, multidrug-resistant TB and extensively drug-resistant TB were introduced as “U88.0” and “U88.1”, respectively. Using reported cases after 2008, a study on the relapse of antimicrobial-resistant TB patients could be conducted, which this study did not investigate. However, this study has a strong point in that it secured representativeness and confidence of data by using national TB reported cases, and calculated the relapse rate of tuberculosis in Korea, and identified factors associated with relapse of TB.

Conflicts of interest

The authors have no conflicts of interest to declare.

Acknowledgements

Acknowledgments

The authors appreciate Dr. Chaeshin Chu from the Korea Centers for Disease Control and Prevention (Cheongju, Korea) for his meticulous review and revision of the manuscript.

Article information

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

• 1. World Health Organization . Global tuberculosis control: WHO report 2014. 2014. World Health Organization; Geneva, Switzerland.
• 2. Ministry of Health and Welfare, Korean National Tuberculosis Association (KNTA) . Report on the 7th tuberculosis prevalence survey in Korea. 1996. Ministry of Health and Welfare, Korean National Tuberculosis Association; Seoul.
• 3. Korea Centers for Disease Control and Prevention . Annual report on the notified tuberculosis patients in Korea, 2010. 2011. Korea Centers for Disease Control and Prevention; Osong, Korea.
• 4. Korea Centers for Disease Control and Prevention . Annual report on the notified tuberculosis patients in Korea, 2013. 2014. Korea Centers for Disease Control and Prevention; Osong, Korea.
• 5. Lew W.J.. Tuberculosis surveillance system in Korea. Tuberc Respir Dis 48(3). 2000 May;298−307.Article
• 6. Jung Y.J., Park I.N., Hong S.B.. The clinical characteristics, diagnosis, treatment, and outcomes of patients with tuberculosis at a private university hospital in Korea. Tuberc Respir Dis 60(2). 2006 Feb;194−204.Article
• 7. Heldal E., Döcker H., Caugant D.A.. Pulmonary tuberculosis in Norwegian patients. The role of reactivation, re-infection and primary infection assessed by previous mass screening data and restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 4(4). 2000 Apr;300−307. PMID: 10777077.PubMed
• 8. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America . Treatment of tuberculosis. Am J Respir Crit Care Med 167(4). 2003 Feb;603−662. PMID: 12588714.ArticlePubMed
• 9. Yoo S.S., Kwon J.S., Kang Y.R.. The clinical characteristics and outcomes of short-term treatment in patients with recurrent pulmonary tuberculosis. Tuberc Respir Dis 64(5). 2008 May;341−346.Article
• 10. Lambert M.L., Hasker E., Van Deun A.. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 3(5). 2003 May;282−287. PMID: 12726976.ArticlePubMed
• 11. Harries A.D., Hargreaves N.J., Kwanjana J.H.. Relapse and recurrent tuberculosis in the context of a National Tuberculosis Control Programme. Trans R Soc Troop Med Hyg 94(3). 2000 May-Jun;247−249.Article
• 12. Sonnenberg P., Murray J., Glynn J.R.. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358(9294). 2001 Nov;1687−1693. PMID: 11728545.ArticlePubMed
• 13. Chang K.C., Leung C.C., Yew W.W.. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170(10). 2004 Nov;1124−1130. PMID: 15374844.ArticlePubMed
• 14. Verve S., Warren R.M., Beyers N.. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171(12). 2005 Jun;1430−1435. PMID: 15831840.ArticlePubMed
• 15. Thomas A., Gopi P.G., Santha T.. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis 9(5). 2005 May;556−561. PMID: 15875929.PubMed
• 16. Tam C.M., Chan S.L., Kam K.M.. Rifapetine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 6(1). 2002 Jan;3−10. PMID: 11931398.PubMed
• 17. Benator D., Bhattacharya M., Zoxeman L.. Refapetine and isoniazid once a week versus rifampcin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 360(9332). 2002 Aug;528−534. PMID: 12241657.ArticlePubMed
• 18. Chang K.C., Leung C.C., Yew W.W.. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 174(10). 2006 Nov;1153−1158. PMID: 16908866.ArticlePubMed
• 19. Edited by Frieden T.: Toman's tuberculosis: case detection, treatment, and monitoring-questions and answers. 2nd ed. 2004. WHO; Geneva, Switzerland: pp 130−138. What is intermittent treatment and what is the scientific bias for intermittency?.
• 20. Vree M., Huong N.T., Duong B.D.. Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int J Tuberc Lung Dis 11(4). 2007 Apr;392−397. PMID: 17394684.PubMed

Figure 1

Number and rate of tuberculosis notification in 2001–2010.

Figure 2

Study population.

Figure 3

Relapse rate of tuberculosis by year (2006–2010).

Figure 4

Proportion of relapse of tuberculosis by year (2006–2010).

Table 1

General characteristics of the study population.

		Total (no.)	Men (no.)	Women (no.)	p
Age (y)	0–9	214	113	101	< 0.0001
	10–19	2,443	1,490	953
	20–29	8,134	4,263	3,871
	30–39	7,299	4,510	2,789
	40–49	7,338	5,251	2,087
	50–59	5,675	4,148	1,527
	60–69	6,293	4,236	2,057
	≥ 70	8,038	4,197	3,841
Region	1	12,085	7,309	4,776	< 0.0001
	2	4,531	2,799	1,732
	3	2,155	1,364	791
	4	1,854	1,186	668
	5	1,386	850	536
	6	1,048	637	411
	7	681	432	249
	8	6,747	4,221	2,526
	9	2,130	1,206	924
	10	1,265	787	478
	11	1,841	1,205	636
	12	2,101	1,329	772
	13	1,946	1,247	699
	14	2,106	1,284	822
	15	3,157	2,089	1,068
	16	401	263	138
Registration	New	34,569	20,631	13,938	< 0.0001
Type	Relapse	5,611	4,095	1,516
	T.A.F.	283	214	69
	T.A.D.	654	496	158
	T.I.	1,812	1,125	687
	Other	2,505	1,647	858
Tuberculosis type	Sputum smear (+) pul TB	15,745	10,251	5,494	< 0.0001
	Sputum smear (−) pul TB	23,437	14,773	8,700
	Extrapulmonary TB	6,216	3,184	3,032
Medication	Only Group 1 drugs	43,276	26,757	16,519	< 0.0001
	With Groups 2–5 drugs	2,158	1,451	707
Total		45,434	28,208	17,226

pul = pulmonary; T.A.D. = treatment after default; T.A.F. = treatment after failure; T.I. = transfer in.

Table 2

Relapse rate of tuberculosis by the characteristics of the study population.

		Relapse				p
		No		Yes
Sex	Men	25,145	(89.14)	3,063	(10.86)	< 0.0001
	Women	15,918	(92.41)	1,308	(7.59)
Age (y)	0–9	207	(96.73)	7	(3.27)	< 0.0001
	10–19	2,256	(92.35)	187	(7.65)
	20–29	7,417	(91.19)	717	(8.81)
	30–39	6,583	(90.19)	716	(9.81)
	40–49	6,494	(88.50)	844	(11.50)
	50–59	5,092	(89.73)	583	(10.27)
	60–69	5,662	(89.97)	631	(10.03)
	≥ 70	7,352	(91.47)	686	(8.53)
Medical	Public	11,412	(91.03)	1,124	(8.97)	0.0004
Facilities	Private	29,651	(90.13)	3,247	(9.87)
Registration	New	31,756	(91.86)	2,813	(8.14)	< 0.0001
Type	Relapse	4,772	(85.05)	839	(14.95)
	T.A.F.	222	(78.45)	61	(21.55)
	T.A.D.	490	(74.92)	164	(25.08)
	T.I.	1,622	(89.51)	190	(10.49)
	Other	2,201	(87.86)	304	(12.14)
TB type	Sputum smear (+) pul TB	13,797	(87.63)	1,948	(12.37)	< 0.0001
	Sputum smear (−) pul TB	21,426	(91.28)	2,047	(8.72)
	Extra–pul TB	5,840	(93.95)	376	(6.05)
Medication	Only Group 1 drugs	39,248	(90.69)	4,028	(9.31)	<.0001
	With Groups 2–5 drugs	1,815	(84.11)	343	(15.89)
Region	1	11,139	(92.17)	946	(7.83)	< 0.0001
	2	3,896	(85.99)	635	(14.01)
	3	1,946	(90.30)	209	(9.70)
	4	1,671	(90.13)	183	(9.87)
	5	1,290	(93.07)	96	(6.93)
	6	943	(89.98)	105	(10.02)
	7	617	(90.60)	64	(9.40)
	8	6,228	(92.31)	519	(7.69)
	9	1,899	(89.15)	231	(10.85)
	10	1,156	(91.38)	109	(8.62)
	11	1,658	(90.06)	183	(9.94)
	12	1,930	(91.86)	171	(8.14)
	13	1,690	(86.84)	256	(13.16)
	14	1,892	(89.84)	214	(10.16)
	15	2,735	(86.63)	422	(13.37)
	16	373	(93.02)	28	(6.98)
Total		41,063	(90.38)	4,371	(9.62)

Data are presented as n (%).

T.A.D. = treatment after default; T.A.F. = treatment after failure; TB = tuberculosis; T.I. = transfer in; pul = pulmonary.

Table 3

Results of multivariate logistic regression analysis.

		OR (95% CI)
Sex	Men	1.33 (1.24–1.43)
	Women	1
Age (y)	0–9	0.43 (0.20–0.93)
	10–19	1
	20–29	1.07 (0.91–1.27)
	30–39	1.10 (0.93–1.31)
	40–49	1.20 (1.01–1.42)
	50–59	1.02 (0.86–1.22)
	60–69	1.04 (0.87–1.23)
	≥70	0.90 (0.76–1.07)
Medical facilities	Public	1
	Private	1.23 (1.14–1.33)
Registration type	New	1
	Relapse	1.76 (1.61–1.91)
	T.A.F.	2.02 (1.50–2.72)
	T.A.D.	3.18 (2.64–3.83)
	T.I.	1.23 (1.05–1.44)
	Other	1.42 (1.25–1.61)
Tuberculosis type	Sputum smear (+) pul TB	1.42 (1.33–1.52)
	Sputum smear (−) pul TB	1
	Extrapulmonary TB	0.70 (0.62–0.78)
Medication	Only Group 1 drugs	1
	With Groups 2–5 drugs	1.32 (1.16–1.50)
Region	1	1
	2	1.85 (1.66–2.06)
	3	1.19 (1.02–1.42)
	4	1.20 (1.01–1.42)
	5	0.85 (0.69–1.06)
	6	1.23 (0.99–1.52)
	7	1.20 (0.92–1.57)
	8	0.98 (0.87–1.10)
	9	1.42 (1.21–1.65)
	10	1.06 (0.86–1.30)
	11	1.29 (1.09–1.53)
	12	1.06 (0.90–1.26)
	13	1.71 (1.47–1.99)
	14	1.28 (1.09–1.50)
	15	1.66 (1.47–1.88)
	16	0.85 (0.58–1.26)

CI = confidence interval; OR = odds ratio; T.A.D. = treatment after default; T.A.F. = treatment after failure; T.I. = transfer in; pul = pulmonary.

Table 4

Results of multivariate logistic regression analysis in public health centers.

		OR (95% CI)
Sex	Men	1.32 (1.14–1.52)
	Women	1
Age (y)	0–9	3.22 (0.32–32.27)
	10–19	1
	20–29	1.02 (0.78–1.35)
	30–39	0.99 (0.75–1.32)
	40–49	0.96 (0.73–1.28)
	50–59	0.98 (0.73–1.33)
	60–69	1.02 (0.76–1.38)
	≥ 70	0.81 (0.60–1.09)
Registration type	New	1
	Relapse	1.87 (1.60–2.18)
	T.A.F.	3.35 (0.47–23.82)
	T.A.D.	2.32 (1.64–3.29)
	T.I.	1.09 (0.81–1.47)
	Other	1.30 (0.85–1.98)
Tuberculosis type	Sputum smear (+) pul TB	1.66 (1.45–1.88)
	Sputum smear (−) pul TB	1
	Extrapulmonary TB	0.81 (0.45–1.48)
Outcome	Cure	1
	Complete	1.39 (0.92–2.11)
	Failure	10.26 (5.95–17.68)
	Default	3.77 (3.03–4.68)
	Transfer out	1.42 (1.17–1.73)
	Other	2.41 (1.80–3.25)
Region	1	1
	2	1.23 (0.96–1.58)
	3	1.25 (0.89–1.75)
	4	0.77 (0.54–1.09)
	5	1.63 (1.03–2.57)
	6	1.40 (0.94–2.09)
	7	0.73 (0.40–1.31)
	8	1.03 (0.84–1.28)
	9	1.18 (0.84–1.68)
	10	0.99 (0.68–1.45)
	11	1.44 (1.05–1.97)
	12	0.90 (0.62–1.30)
	13	1.47 (1.10–1.96)
	14	1.35 (1.02–1.79)
	15	1.77 (1.35–2.32)
	16	0.57 (0.30–1.09)

CI = confidence interval; OR = odds ratio; pul = pulmonary; T.A.F. = treatment after failure, T.A.D. = treatment after default, T.I. = transfer in.

Table 5

Relapse rate of tuberculosis in public health centers.

		Relapse				p
		No		Yes
Sex	Men	7,511	(90.0)	839	(10.0)	< 0.0001
	Women	3,901	(93.2)	285	(6.8)
Age (y)	0–9	4	(80.0)	1	(20.0)	0.002
	10–19	1,115	(93.5)	78	(6.5)
	20–29	2,377	(91.6)	218	(8.4)
	30–39	1,855	(90.7)	190	(9.3)
	40–49	1,762	(89.8)	200	(10.2)
	50–59	1,195	(89.7)	138	(10.3)
	60–69	1,411	(90.0)	156	(10.0)
	≥ 70	1,693	(92.2)	143	(7.8)
Registration	New	8,684	(92.5)	705	(7.5)	< 0.0001
Type	Relapse	1,655	(85.1)	289	(14.9)
	T.A.F	3	(60.0)	2	(40.0)
	T.A.D	178	(78.8)	48	(21.2)
	T.I	677	(92.6)	54	(7.4)
	Other	215	(89.2)	26	(10.8)
TB type	Sputum smear (+) pul TB	4,585	(88.2)	616	(11.8)	< 0.0001
	Sputum smear (−) pul TB	6,615	(93.0)	496	(7.0)
	Extrapulmonary TB	212	(94.6)	12	(5.4)
Outcome	Cure	9,366	(92.7)	735	(7.3)	< 0.0001
	Complete	217	(88.9)	27	(11.1)
	Failure	28	(50.0)	28	(50.0)
	Default	428	(76.0)	135	(24.0)
	Transfer out	1,083	(88.6)	139	(11.4)
	Other	290	(82.9)	60	(17.1)
Region	1	2,109	(91.54)	195	(8.46)	0.0002
	2	967	(89.37)	115	(10.63)
	3	430	(89.77)	49	(10.23)
	4	606	(93.66)	41	(6.34)
	5	212	(89.83)	24	(10.17)
	6	277	(89.35)	33	(10.65)
	7	223	(94.49)	13	(5.51)
	8	2,422	(92.09)	208	(7.91)
	9	468	(90.87)	47	(9.13)
	10	438	(92.41)	36	(7.59)
	11	539	(89.68)	62	(10.32)
	12	491	(92.99)	37	(7.01)
	13	667	(89.65)	77	(10.35)
	14	716	(89.50)	84	(10.50)
	15	655	(87.68)	92	(12.32)
	16	192	(94.58)	11	(5.42)
Total		11,412	(91.0)	1,124	(9.0)

Data are presented as n (%).

pul = pulmonary; T.A.D. = treatment after default, T.A.F. = treatment after failure; T.I. = transfer in.

Figure & Data

References

Citations

Citations to this article as recorded by  

• Sex differences in the impact of diabetes mellitus on tuberculosis recurrence: a retrospective national cohort study
  Dararat Eksombatchai, Dawoon Jeong, Jeongha Mok, Doosoo Jeon, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Hongjo Choi, Young Ae Kang
  International Journal of Infectious Diseases.2023; 127: 1.     CrossRef
• Recurrence of pulmonary tuberculosis in India: Findings from the 2019–2021 nationwide community-based TB prevalence survey
  Prathiksha Giridharan, Sriram Selvaraju, Raghuram Rao, Kiran Rade, Kannan Thiruvengadam, Smita Asthana, Rakesh Balachandar, Sampada Dipak Bangar, Avi Kumar Bansal, Jyothi Bhat, Debjit Chakraborty, Vishal Chopra, Dasarathi Das, Shanta Dutta, Kangjam Rekha
  PLOS ONE.2023; 18(12): e0294254.     CrossRef
• Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study
  Hin Moi Youn, Moon-Kyung Shin, Dawoon Jeong, Hee-Jin Kim, Hongjo Choi, Young Ae Kang, Jun Hyeok Lim
  PLOS ONE.2022; 17(6): e0268290.     CrossRef
• Facteurs de risque de récurrence de tuberculose pulmonaire bactériologique confirmé à Kisangani (République démocratique du Congo)
  Catherine Marie Nomopuane Kabudri, Shadrack Kandala Ngianga II, Léon Okenge Ngongo
  Santé Publique.2022; Vol. 34(4): 591.     CrossRef
• Predicting the impact of control strategies on the tuberculosis burden in South and North Korea using a mathematical model
  Hyunwoo Cho, Youngmok Park, Jeongjoo Seok, Joon Sup Yeom, Jun Yong Choi, Hee Jin Kim, Young Ae Kang, Jeehyun Lee
  BMJ Global Health.2021; 6(10): e005953.     CrossRef
• Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations
  Johan Vekemans, Michael James Brennan, Mark Hatherill, Lewis Schrager, Bernard Fritzell, Kathryn Rutkowski, Beatrice De Vos, Matteo Zignol, Georges Thiry, Ann M. Ginsberg, Barry Walker
  Vaccine.2020; 38(2): 135.     CrossRef
• Rate and risk factors of recurrent tuberculosis in Yemen: a 5-year prospective study
  Mohammed Saif Anaam, Alian A. Alrasheedy, Saud Alsahali, Saeed O. Alfadly, Adel H. Aldhubhani
  Infectious Diseases.2020; 52(3): 161.     CrossRef
• Small Animal Model of Post-chemotherapy Tuberculosis Relapse in the Setting of HIV Co-infection
  Matthew B. Huante, Tais B. Saito, Rebecca J. Nusbaum, Kubra F. Naqvi, Sadhana Chauhan, Robert L. Hunter, Jeffrey K. Actor, Jai S. Rudra, Mark A. Endsley, Joshua G. Lisinicchia, Benjamin B. Gelman, Janice J. Endsley
  Frontiers in Cellular and Infection Microbiology.2020;[Epub]     CrossRef
• Proteomic analysis of infected primary human leucocytes revealed PSTK as potential treatment-monitoring marker for active and latent tuberculosis
  Benjawan Kaewseekhao, Sittiruk Roytrakul, Yodying Yingchutrakul, Kanin Salao, Wipa Reechaipichitkul, Kiatichai Faksri, HASNAIN SEYED EHTESHAM
  PLOS ONE.2020; 15(4): e0231834.     CrossRef
• The association between proton pump inhibitor use and the risk of tuberculosis: A case‐control study
  Hyun Jin Song, Haesuk Park, Susan Park, Jin‐Won Kwon
  Pharmacoepidemiology and Drug Safety.2019; 28(6): 830.     CrossRef
• Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing
  Laila Parvaresh, Taryn Crighton, Elena Martinez, Andrea Bustamante, Sharon Chen, Vitali Sintchenko
  BMC Infectious Diseases.2018;[Epub]     CrossRef
• Treatment Outcomes of Patients Treated for Pulmonary Tuberculosis after Undergoing Gastrectomy
  In Young Jung, Moo Hyun Kim, Woo Yong Jeong, Mi Young Ahn, Yong Duk Jeon, Hea Won Ahn, Jin Young Ahn, Je Eun Song, Dong Hyun Oh, Yong Chan Kim, Eun Jin Kim, Su Jin Jeong, Nam Su Ku, June Myung Kim, Jun Yong Choi
  The Tohoku Journal of Experimental Medicine.2016; 240(4): 281.     CrossRef
• Is Tuberculosis Still the Number One Infectious Disease in Korea?
  Hae-Wol Cho, Chaeshin Chu
  Osong Public Health and Research Perspectives.2014; 5: S1.     CrossRef